In recent trading session, Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) saw 0.67 million shares changing hands at last check today with its beta currently measuring 1.91. Company’s recent per share price level of $5.66 trading at $0.19 or 3.38% at last check today assigns it a market valuation of $1.17B. That most recent trading price of BCRX’s stock is at a discount of -60.07% from its 52-week high price of $9.06 and is indicating a premium of 14.84% from its 52-week low price of $4.82. Taking a look at company’s average trading volume which gives us an average trading volume of 3.30 million if we extend that period to 3-months.
Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) trade information
Upright in the green today for gaining 3.38%, in the last five days BCRX remained trading in the green while hitting it’s week-highest on Thursday, 03/21/24 when the stock touched $5.66 price level, adding 3.41% to its value on the day. Biocryst Pharmaceuticals Inc.’s shares saw a change of -5.59% in year-to-date performance and have moved 15.64% in past 5-day. Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) showed a performance of 0.09% in past 30-days.
Biocryst Pharmaceuticals Inc. (BCRX) estimates and forecasts
Statistics highlight that Biocryst Pharmaceuticals Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -20.46% of value to its shares in past 6 months, showing an annual growth rate of 38.00% while that of industry is 11.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 25.00% in the current quarter and calculating 60.00% increase in the next quarter. This year revenue growth is estimated to rise 19.40% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $86.29 million for the same. And 9 analysts are in estimates of company making revenue of $98.6 million in the next quarter that will end on Jun 2024. Company posted $68.78 million and $82.49 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 25.50% while estimating it to be 19.50% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -3.73% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 46.44% while estimates for its earnings growth in next 5 years are of 44.80%.
BCRX Dividends
Biocryst Pharmaceuticals Inc. is more likely to be releasing its next quarterly report between May 01 and May 06 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s Major holders
Insiders are in possession of 1.22% of company’s total shares while institution are holding 88.26 percent of that, with stock having share float percentage of 89.35%. Investors also watch the number of corporate investors in a company very closely, which is 88.26% institutions for Biocryst Pharmaceuticals Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at BCRX for having 18.68 million shares of worth $105.74 million. And as of Dec 30, 2023, it was holding 9.06% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group Inc, which was holding about 17.76 million shares on Dec 30, 2023. The number of shares represents firm’s hold over 8.62% of outstanding shares, having a total worth of $100.54 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jan 30, 2024, the former fund manager was holding 8.35 million shares of worth $47.24 million or 4.05% of the total outstanding shares. The later fund manager was in possession of 6.93 million shares on Dec 30, 2023, making its stake of worth around $39.21 million in the company or a holder of 3.36% of company’s stock.
